Indiana
facility will combine research, manufacturing and the latest
technology to innovate new production methods and scale global
access to clinical supply for Lilly's growing pipeline
Opening in late 2027, the facility will
increase Lilly's total capital commitment in the United States to more than $23 billion since 2020
INDIANAPOLIS, Oct. 2, 2024
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a
$4.5 billion investment to create the
Lilly Medicine Foundry, a new center for advanced manufacturing and
drug development. This unique facility will give Lilly the ability
to research new ways of producing medicines, while also scaling up
manufacturing of medicines for clinical trials. The first-ever
facility of its kind, combining research and manufacturing in a
single location, the Medicine Foundry will be located in
Indiana's LEAP Research and
Innovation District in Lebanon,
Indiana, and will expand the company's investment there to
more than $13 billion.
"As we accelerate our work to discover new medicines for the
toughest diseases, we're continuing to invest in state-of-the-art
infrastructure to support our growing pipeline," said David A. Ricks, Lilly's chair and CEO. "In
addition to supplying high-quality medicine for our clinical
studies, this new complex will further strengthen our process
development and scale up our manufacturing capabilities to speed
delivery of next-generation medicines to patients around the
world."
The Medicine Foundry will allow Lilly to further develop
innovative solutions to optimize manufacturing processes and
increase capacity for clinical trial medicines, while also reducing
costs and environmental impact. The flexible design of this new
facility will enable production of various molecular therapies,
including drug substances for small molecules, biologics and
nucleic acid therapies. New technologies developed at the Medicine
Foundry will be transferred to Lilly's other
manufacturing sites for full-scale production. The site's
location in LEAP will support close collaboration with Lilly
Research Laboratories' teams in Indianapolis and Lilly's manufacturing sites
in Lebanon.
The State of Indiana will
support the new site with infrastructure improvements for roads,
water, electricity and other utilities. The state will also offer
economic incentives tied to Lilly's investment and employment goals
in Lebanon. Once fully
operational, the Medicine Foundry is expected to add 400 full-time
jobs for highly skilled workers including engineers, scientists,
operations personnel and lab technicians.
"Lilly's continued investment in Indiana solidifies our state's role as a hub
for cutting-edge science and technology,"
said Indiana Governor Eric J. Holcomb. "For nearly
150 years, Lilly has been committed to growing its roots and reach
in Indiana, cultivating local
talent, and driving scientific advancements that benefit patients
around the world. I couldn't be more excited about the
opportunities Lilly's Medicine Foundry will bring to communities
throughout our great state."
"Lilly's increased investment in Indiana is creating tremendous new career
opportunities for Hoosiers," said Indiana Secretary of Commerce David Rosenberg. "The LEAP district in
Lebanon is quickly becoming an
international destination, with $18
billion in committed capital investment on 2,300 acres since
its launch in 2022. LEAP and the Hardtech Corridor are attracting
global leaders, talent and innovation to Indiana."
This new facility will add to Lilly's previous manufacturing
commitments in Lebanon:
- In May 2022, Lilly announced
plans to invest $2.1 billion in two
new manufacturing sites in Lebanon
to expand its network for active ingredients and new modalities,
such as genetic medicines.
- In April 2023, Lilly broke ground
on these facilities and announced an additional $1.6 billion investment.
- In May 2024, Lilly announced an
additional $5.3 billion commitment to
enhance capacity to manufacture active pharmaceutical ingredients
for its latest diabetes and obesity medicines. This milestone
marked the largest single investment in active pharmaceutical
ingredients production in U.S. history.
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help tens of millions of people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Forward-Looking Statement
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) including about planned capital investments in new
manufacturing capacity and related initiatives and reflects Lilly's
current beliefs and expectations. However, as with any such
undertaking, there are substantial risks and uncertainties in the
manufacturing process, development and commercialization of
pharmaceutical products any of which could impact the overall
commercial success of our products, and as related to cost,
completion timing, expected capacity, personnel, and other factors
which could impact expected benefits of the capacity expansion and
related initiatives. For further discussion of these and other
risks and uncertainties, see Lilly's most recent Form 10-K and Form
10-Q filings with the United States Securities and Exchange
Commission. Except as required by law, Lilly undertakes no duty to
update forward-looking statements to reflect events after the date
of this release.
#
#
#
Additional Quote Options for Media Use
U.S. Secretary of Commerce Gina
Raimondo: "This kind of investment will help
the United States maintain
leadership in advanced manufacturing and accelerate innovation,"
said U.S. Secretary of Commerce Gina
Raimondo. "It will complement the $51
million Tech Hubs investment the Biden-Harris administration
announced in July to advance Central
Indiana's global leadership in biotechnology and
biomanufacturing and strengthen the nation's biotechnology supply
chain. Eli Lilly plays a critical role in the Central Indiana
Tech Hub."
U.S. Congressman Jim
Banks: "Lilly's longstanding commitment to Indiana and latest investment are a testament
to our state's talented workforce and innovative business
environment. The Lilly Medicine Foundry will be a state-of-the-art
facility that leads the world in biotechnology developments and
creates hundreds of good paying jobs for Hoosiers."
Refer to: Stefanie Prodouz; stefanie.prodouz@lilly.com;
+1-317-287-9899 (Media)
Joe Fletcher;
jfletcher@lilly.com; +1-317-296-2884 (Investors)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-announces-new-4-5-billion-site---the-lilly-medicine-foundry---to-drive-innovation-in-drug-production-and-make-medicines-for-clinical-trials-302264905.html
SOURCE Eli Lilly and Company